Trial Profile
A dose finding study of the safety of gemtuzumab ozogamicin combined with conventional chemotherapy for patients with relapsed or refractory acute myeloid leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2007
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Asparaginase; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 06 Aug 2007 Status changed from in progress to completed.
- 13 Sep 2005 New trial record.